164 related articles for article (PubMed ID: 33230179)
1. Comprehensive assessment of TP53 loss of function using multiple combinatorial mutagenesis libraries.
Carbonnier V; Leroy B; Rosenberg S; Soussi T
Sci Rep; 2020 Nov; 10(1):20368. PubMed ID: 33230179
[TBL] [Abstract][Full Text] [Related]
2. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutations, expression and interaction networks in human cancers.
Wang X; Sun Q
Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era.
Soussi T; Leroy B; Taschner PE
Hum Mutat; 2014 Jun; 35(6):766-78. PubMed ID: 24729566
[TBL] [Abstract][Full Text] [Related]
5. TP53 isoform junction reads based analysis in malignant and normal contexts.
Vural S; Chang LC; Yee LM; Sonkin D
Sci Rep; 2021 Aug; 11(1):17275. PubMed ID: 34446762
[TBL] [Abstract][Full Text] [Related]
6. Allelic expression imbalance of TP53 mutated and polymorphic alleles in head and neck tumors.
Ganci F; Conti S; Fontemaggi G; Manciocco V; Donzelli S; Covello R; Muti P; Strano S; Blandino G; Spriano G
OMICS; 2011 Jun; 15(6):375-81. PubMed ID: 21348641
[TBL] [Abstract][Full Text] [Related]
7. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
8. TP53 tumor suppressor gene: a model for investigating human mutagenesis.
Caron de Fromentel C; Soussi T
Genes Chromosomes Cancer; 1992 Jan; 4(1):1-15. PubMed ID: 1377002
[TBL] [Abstract][Full Text] [Related]
9. Mutational processes shape the landscape of TP53 mutations in human cancer.
Giacomelli AO; Yang X; Lintner RE; McFarland JM; Duby M; Kim J; Howard TP; Takeda DY; Ly SH; Kim E; Gannon HS; Hurhula B; Sharpe T; Goodale A; Fritchman B; Steelman S; Vazquez F; Tsherniak A; Aguirre AJ; Doench JG; Piccioni F; Roberts CWM; Meyerson M; Getz G; Johannessen CM; Root DE; Hahn WC
Nat Genet; 2018 Oct; 50(10):1381-1387. PubMed ID: 30224644
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.
Petitjean A; Achatz MI; Borresen-Dale AL; Hainaut P; Olivier M
Oncogene; 2007 Apr; 26(15):2157-65. PubMed ID: 17401424
[TBL] [Abstract][Full Text] [Related]
11. FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.
Waters CE; Saldivar JC; Amin ZA; Schrock MS; Huebner K
Oncotarget; 2015 Feb; 6(5):3409-19. PubMed ID: 25401976
[TBL] [Abstract][Full Text] [Related]
12. Emerging Non-Canonical Functions and Regulation of p53.
Ranjan A; Iwakuma T
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29597309
[TBL] [Abstract][Full Text] [Related]
13. A novel loss-of-function mutation in TP53 in an endometrial cancer cell line and uterine papillary serous carcinoma model.
Liu Z; Wan G; Heaphy C; Bisoffi M; Griffith JK; Hu CA
Mol Cell Biochem; 2007 Mar; 297(1-2):179-87. PubMed ID: 17119852
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in p53.
D'Orazi G
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33546313
[TBL] [Abstract][Full Text] [Related]
15. Damage-inducible intragenic demethylation of the human TP53 tumor suppressor gene is associated with transcription from an alternative intronic promoter.
Blackburn J; Roden DL; Ng R; Wu J; Bosman A; Epstein RJ
Mol Carcinog; 2016 Dec; 55(12):1940-1951. PubMed ID: 26676339
[TBL] [Abstract][Full Text] [Related]
16. TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database.
Li VD; Li KH; Li JT
J Cancer Res Clin Oncol; 2019 Mar; 145(3):625-636. PubMed ID: 30542790
[TBL] [Abstract][Full Text] [Related]
17. Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia.
Schittenhelm MM; Walter B; Tsintari V; Federmann B; Bajrami Saipi M; Akmut F; Illing B; Mau-Holzmann U; Fend F; Lopez CD; Kampa-Schittenhelm KM
EBioMedicine; 2019 Apr; 42():340-351. PubMed ID: 30952616
[TBL] [Abstract][Full Text] [Related]
18. Recommended Guidelines for Validation, Quality Control, and Reporting of
Leroy B; Ballinger ML; Baran-Marszak F; Bond GL; Braithwaite A; Concin N; Donehower LA; El-Deiry WS; Fenaux P; Gaidano G; Langerød A; Hellstrom-Lindberg E; Iggo R; Lehmann-Che J; Mai PL; Malkin D; Moll UM; Myers JN; Nichols KE; Pospisilova S; Ashton-Prolla P; Rossi D; Savage SA; Strong LC; Tonin PN; Zeillinger R; Zenz T; Fraumeni JF; Taschner PE; Hainaut P; Soussi T
Cancer Res; 2017 Mar; 77(6):1250-1260. PubMed ID: 28254861
[TBL] [Abstract][Full Text] [Related]
19. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf
Chapeau EA; Gembarska A; Durand EY; Mandon E; Estadieu C; Romanet V; Wiesmann M; Tiedt R; Lehar J; de Weck A; Rad R; Barys L; Jeay S; Ferretti S; Kauffmann A; Sutter E; Grevot A; Moulin P; Murakami M; Sellers WR; Hofmann F; Jensen MR
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3151-3156. PubMed ID: 28265066
[TBL] [Abstract][Full Text] [Related]
20. Characterization of germline TP53 splicing mutations and their genetic and functional analysis.
Varley JM; Attwooll C; White G; McGown G; Thorncroft M; Kelsey AM; Greaves M; Boyle J; Birch JM
Oncogene; 2001 May; 20(21):2647-54. PubMed ID: 11420676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
